Leukemia Research Reports最新文献

{"title":"CLINICAL CHARACTERISTICS AND OUTCOMES OF MYELODYSPLASTIC NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH MECOM REARRANGEMENT: RESULTS FROM A NATIONWIDE MULTICENTER STUDY.","authors":"C. Polprasert ,&nbsp;C. Chanswangphuwana ,&nbsp;W. Owattanapanich ,&nbsp;S. Kungwankiattichai ,&nbsp;E. Rattarittamrong ,&nbsp;T. Rattanathammethee ,&nbsp;A. Tantiworawit ,&nbsp;W. Limvorapitak ,&nbsp;S. Saengboon ,&nbsp;P. Niparuck ,&nbsp;T. Puavilai ,&nbsp;J. Julamanee ,&nbsp;P. Saelue ,&nbsp;C. Wanitpongpun ,&nbsp;C. Nakhakes ,&nbsp;K. Prayongratana ,&nbsp;E. Karoopongse ,&nbsp;P. Rojnuckarin ,&nbsp;C. Sriswasdi","doi":"10.1016/j.lrr.2024.100420","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100420","url":null,"abstract":"<div><h3>Introduction</h3><p>“AML with <em>MECOM</em> rearrangement” was recently categorized by WHO classification 2022 regardless of blast count, which included those present with MDS and AML into this group. We aim to explore frequency, clinical characteristics, and outcomes in this subtype among Thai myeloid neoplasms.</p></div><div><h3>Methods</h3><p>MDS and AML data was collected from a multicenter study group. MDS and AML with <em>MECOM</em> rearrangements were analyzed and compared with other subtypes.</p></div><div><h3>Results</h3><p>A total of 15 cases with <em>MECOM</em> rearrangement were detected, 5/166 (3%) were MDS while 10/1082 (0.9%) were AML. Eleven of 15 cases (73%) were female. MDS and AML with <em>MECOM</em> rearrangement showed lower hemoglobin, but higher platelet counts compared to others. Three MDS with <em>MECOM</em> rearrangement patients received azacitidine-based regimens and achieved complete hematologic response. In AML cases receiving intensive chemotherapy, <em>MECOM</em> rearrangement subgroup showed lower complete response (CR) rate compared to others (0% vs. 39.6%). Of note, among 10 AML with <em>MECOM</em> rearrangement, 7 patients received intensive chemotherapy but none of them responded. When combining 5 MDS and 10 AML with <em>MECOM</em> rearrangements, survival rate is comparable to the adverse group of AML and the very high risk group MDS with a 1-year survival rate of 27.5% (<strong>Figure 1A and 1B</strong>).</p></div><div><h3>Conclusions</h3><p>In conclusion, MDS and AML with <em>MECOM</em> rearrangements are rare subtype, more common in female gender and associated with poor prognosis. Chemotherapy should be avoided, hypomethylating agent showed benefit. Novel therapy targeting <em>MECOM</em> gene should be further explored.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000104/pdfft?md5=bc692c203355bb847376fc64299bd1a9&pid=1-s2.0-S2213048924000104-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY","authors":"T. Ueda ,&nbsp;K. Fukushima ,&nbsp;Y. Nannya ,&nbsp;A. Hino ,&nbsp;M. Hamada ,&nbsp;Y. Mizutani ,&nbsp;E. Mizuta ,&nbsp;C. Hasegawa ,&nbsp;Y. Yamaguchi ,&nbsp;R. Kurashige ,&nbsp;R. Nakai ,&nbsp;S. Kusakabe ,&nbsp;M. Ichii ,&nbsp;J. Fujita ,&nbsp;N. Hosen","doi":"10.1016/j.lrr.2024.100448","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100448","url":null,"abstract":"<div><h3>Introduction</h3><p>The prognosis of TP53 biallelic-mutated AML/MDS is severely poor. Azacitidine, venetoclax combination therapy (Aza/Ven) was shown to be effective and tolerable for AML patients who cannot receive standard chemotherapy and the efficacy even for adverse risk AML is expected.</p></div><div><h3>Methods</h3><p>We report 3 cases of TP53 biallelic-mutated AML/MDS, successfully bridged to allo-HSCT by Aza/Ven.</p></div><div><h3>Results</h3><p>Case 1 A 60-year-old male was diagnosed with MDS-MLD with complex karyotypes. TP53 p.V216G mutation (VAF 0.859) was detected by NGS. Because the disease progressed to MDS-EB1, one cycle of Aza/Ven was administered for disease control. No severe side effects happened during Aza/Ven. After allo-HSCT, CR was achieved and maintained for over 6 months. Case 2 A 57-year-old male was diagnosed as MDS-EB1 with complex karyotypes including -17. TP53 p.V216G mutation (VAF 0.733) and DNMT3A p.C497Y mutation were detected by NGS. After two cycles of Aza/Ven, myeloblasts in BM was decreased (9.4%→2.8%) without severe side effects. Although he received allo-HSCT, the disease relapsed. Case 3 A 62-year-old male was diagnosed with MDS-EB2. He has several complications including interstitial pneumonia. Although he received two cycles of Aza single therapy, the disease progressed. BM analysis revealed the complex karyotypes, including -17. TP53 p.R241 mutation (VAF 0.88) was detected by NGS. Thus, his treatment was switched to Aza/Ven. After two cycles of Aza/Ven, the disease did not progress, and no severe side effects were seen. He has just received allo-HSCT.</p></div><div><h3>Conclusions</h3><p>Aza/Ven could be an effective treatment option as a bridging therapy toward allo-HSCT even in TP53 biallelic-mutated AML/MDS cases.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000384/pdfft?md5=f921afd9eb4cf279928f008e986b7c5f&pid=1-s2.0-S2213048924000384-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A tertiary care centre experience with Elranatamab: A report of three cases","authors":"Disha Kakkar,&nbsp;Aakanksha Singh,&nbsp;Reshmi Harikumar Pillai,&nbsp;Tribikram Panda,&nbsp;Roy J Palatty,&nbsp;Rohan Halder,&nbsp;Narendra Agrawal,&nbsp;Dinesh Bhurani","doi":"10.1016/j.lrr.2024.100466","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100466","url":null,"abstract":"<div><h3>Introduction</h3><p>The introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the treatment paradigm of multiple myeloma. With the advent of these new therapeutic options, life expectancy has substantially increased for myeloma patients which has led to an increased number of patients with triple-class refractory disease. Thus, there remains an unmet need for effective novel therapies with good tolerability and safety profile. Elranatamab, is the most widely used bispecific antibody currently in the Indian setting. However, it has only been used on a clinical trial basis till now, and real-world data especially in the Indian setting is missing. Here, we present our experience with three cases of multi-line treated relapsed/refractory multiple myeloma on elranatamab monotherapy.</p></div><div><h3>Case report</h3><p>We here discuss three of our patients with triple class refractory multiple myeloma who recieved elranatamab monotherapy. While one of our patient had been switched to fortnightly treatment, two patients were still continuing weekly treatment. The common adverse effects observed were grade 1–2 cytokine release syndrome, cytopenias, CMV reactivation and hypo-gammaglobulinemia. While two of our patients are doing well, one patient had grade 3 neurological toxicity, likely drug related and succumbed.</p></div><div><h3>Discussion</h3><p>B-cell maturation antigen is highly expressed on mature B cells and is critical for the survival and proliferation of plasma cells. It has emerged as a novel target for anti-myeloma therapies in the form of bispecific cell engager, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies.The phase II MM3 trial showed a promising efficacy with an ORR of 61% with a CR rate of &gt;35%. With a median follow-up of 14.7 months, the median PFS was not reached and the 15-month PFS rate was 50.9%. While it is too early to comment on long term survival with the monotherapy, we here discuss response of Indian patients in the real world setting.</p></div><div><h3>Conclusion</h3><p>Elranatamab monotherapy could prove to be an efficacious option for the treatment of relapsed /refractory multiple myeloma patients with triple-class refractory disease, with limited therapeutic options. However, patients need to be screened for infectious complications with appropriate prophylaxis and immunoglobulin replacement, if required. Also, a high suspicion is required for the neurological complications of the drug and a longitudinal neuro-cognitive screening is required for the patients.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000566/pdfft?md5=5252d35632d730f7e83f6a703b11d1b6&pid=1-s2.0-S2213048924000566-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141314207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of AMeD syndrome with isochromosome 1q treated with allogeneic stem cell transplantation","authors":"Mari Kagajo (Data curation) ,&nbsp;Kyoko Moritani ,&nbsp;Mayumi Iwamoto ,&nbsp;Machiko Miyamoto ,&nbsp;Tsuyoshi Imai ,&nbsp;Motoharu Hamada ,&nbsp;Manabu Wakamatsu ,&nbsp;Hideki Muramatsu ,&nbsp;Minenori Eguchi-Ishimae ,&nbsp;Mariko Eguchi","doi":"10.1016/j.lrr.2024.100476","DOIUrl":"10.1016/j.lrr.2024.100476","url":null,"abstract":"<div><p>AMeD syndrome is characterized by aplastic anemia, mental retardation, short stature, and microcephaly and is caused by digenic mutations in the aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 5 (ADH5) genes. We have successfully performed hematopoietic stem cell transplantation in two patients with AMeD syndrome and isochromosome 1q. AMeD syndrome with myelodysplastic syndrome or acute myeloblastic leukemia generally has a poor prognosis; however, early diagnosis may improve treatment response. Although the gain of 1q has been considered as a form of early clonal evolution in Fanconi anemia, it may be an equally important finding observed in AMeD syndrome.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000669/pdfft?md5=40632536a77ef5fb25bd12487f3689aa&pid=1-s2.0-S2213048924000669-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report","authors":"Elrazi A Ali ,&nbsp;Monika Jain ,&nbsp;Akriti Pokhrel ,&nbsp;Unni Mooppan ,&nbsp;Jen chin Wang","doi":"10.1016/j.lrr.2024.100473","DOIUrl":"10.1016/j.lrr.2024.100473","url":null,"abstract":"<div><p>Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000633/pdfft?md5=140b9fa865047a5c64dc0e21482883d9&pid=1-s2.0-S2213048924000633-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India","authors":"Akhilesh S ,&nbsp;Arunim shah ,&nbsp;Ashish Ashish ,&nbsp;Nitish kumar Singh ,&nbsp;Manpreet Kaur ,&nbsp;Abhay kumar Yadav ,&nbsp;Royana singh","doi":"10.1016/j.lrr.2023.100403","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100403","url":null,"abstract":"<div><h3>Background</h3><p>Chronic Myeloid Leukemia is characterized by the presence of the Philadelphia Chromosome (Ph) which contains the <em>BCR::ABL1</em> fusion gene that occurs due to a reciprocal translocation between chromosomes 9 and 22. This accounts for up to 15 % of all adult leukemias <span>[1]</span>. Most patients treated with first line tyrosine kinase inhibitor (TKI) imatinib achieve durable response but may undergo relapse at some stage <span>[2]</span>. The most important mechanism that may confer imatinib resistance is point mutation within <em>BCR::ABL</em> kinase domain. Other generation <em>ABL</em> tyrosine kinase inhibitors such as dasatinib, nilotinib, bosutinib and ponatinib help to overcome imatinib resistance <span>[3]</span>. Sensitivity of the patient to each of the above TKIs depends upon the individual candidate mutation present. Thus, it is important to perform mutation analysis for effective therapeutic management of CML patients once they show imatinib resistance. We used direct sequencing to identify the different types of mutations responsible for resistance of imatinib treatment from north India.</p></div><div><h3>Methods</h3><p>In this study, the patient resistance for the imatinib were analyzed for <em>BCR::ABL</em> kinase domain mutation by direct sequencing and the detected mutations along with their percentage prevalence were reported.</p></div><div><h3>Results</h3><p>329 patients with CML-CP were analyzed for <em>BCR::ABL</em> kinase domain mutation. Total 66 (20.06 %) patients out of 329 had mutation in at least one of the domains of <em>BCR::ABL</em> conferring resistance to different generations of TKI. Mutations in <em>BCR::ABL</em> kinase domain was observed in different domain of <em>BCR::ABL</em>. ATP binding P-Loop (42.42 %), Direct binding site (36.36 %), C-Loop (10.60 %), A-Loop (6.06 %), SH2 contact (3.03 %), SH3 contact (1.51 %).</p></div><div><h3>Conclusion</h3><p>Total 20.06 % patients (66/329) show mutation in at least one of the structural motifs of BCR-ABL kinase domain, which further confer the resistance to a particular generation of TKI.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000432/pdfft?md5=bf82e8b3c1ff3975f5f6413a87aa9b7c&pid=1-s2.0-S2213048923000432-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139038402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Bartonella sp. infection relevant in hematological malignancies in HIV-negative patients? A literature review","authors":"Elisa Nunes Secamilli ,&nbsp;Marina Rovani Drummond ,&nbsp;Juliana Yumi Massuda Serrano ,&nbsp;Rafael Fantelli Stelini ,&nbsp;Maria Leticia Cintra ,&nbsp;Paulo Eduardo Neves Ferreira Velho","doi":"10.1016/j.lrr.2023.100402","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100402","url":null,"abstract":"<div><p>Bartonelloses are diseases caused by Bartonella sp., transmitted to humans by blood sucking arthropod vectors. Clinical presentations include bacillary angiomatosis, cat scratch disease and atypical forms. We performed a review of cases of bartonelloses and hematological malignancies published in HIV-negative patients. Terms used were Bartonella or Bacillary Angiomatosis and Leukemia, Lymphoma, Multiple Myeloma, or Cancer. Fifteen cases met our criteria. Clinical presentations included bacillary angiomatosis, chronic fever, chronic lymphadenopathy, osteomyelitis, neuroretinitis, chronic anemia and hepatosplenic peliosis. Fourteen patients were asymptomatic after antibiotic therapy, and one died before antibiotic treatment. Clinicians should be suspicious of Bartonella sp. infections in immunocompromised patients.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000420/pdfft?md5=1a9b43ce6cf272c312719dbe2980b7ad&pid=1-s2.0-S2213048923000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138738946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and clinical characteristics of adult acute lymphoblastic leukemia patients in Chile: A single-center analysis","authors":"Joaquín Jerez ,&nbsp;Valentina Goldschmidt ,&nbsp;María Carolina Guerra ,&nbsp;José Luis Briones ,&nbsp;Carlos Torres ,&nbsp;Sebastián Hidalgo ,&nbsp;Raimundo Gazitúa","doi":"10.1016/j.lrr.2023.100405","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100405","url":null,"abstract":"<div><h3>Background</h3><p>Acute lymphoblastic leukemia represents 20% of acute leukemias in adults. Currently, there is limited data in Chile regarding the clinical, cytogenetic, and prognostic characteristics of this condition.</p></div><div><h3>Methods</h3><p>This is a retrospective, observational, and descriptive study of 67 patients treated for acute lymphoblastic leukemia at the Arturo Lopez Perez Foundation between 2018 and 2021. The main objective is to evaluate epidemiological and clinical characteristics, as well as identifying factors associated with improved overall survival and/or progression-free survival.</p></div><div><h3>Results</h3><p>88% of the cases were B-lineage, mainly the common B phenotype. Cytogenetic analysis was performed in less than 50% of the patients, with lower yield than expected according to the literature. Molecular testing was performed in 86.5% of the patients, with the most frequent alteration being BCR-ABL. No study was performed to search for Ph-like abnormalities. The rate of complete response after induction was 83.3%, the majority of patients having negative minimal residual disease. Only 12% of the patients received consolidation with allogenic bone marrow transplant. At 2 years, the overall survival was 69% and the progression-free survival was 59%.</p></div><div><h3>Conclusion</h3><p>The results in terms of overall survival and progression-free survival are similar to those reported in the literature. Important diagnostic gaps prevent adequate prognostic characterization. Allogeneic consolidation transplantation was performed in a lower percentage than expected, highlighting the national deficit in access to this treatment.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000456/pdfft?md5=0ad92285cf180884a604004f85fa3f0a&pid=1-s2.0-S2213048923000456-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138657109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare association of a high grade glioblastoma, cerebral abscess and acute lymphoblastic leukemia in a child with Noonan syndrome","authors":"Wiem Boufrikha ,&nbsp;Rim Rakez ,&nbsp;Inaam Bizid ,&nbsp;M.Maher Hadhri ,&nbsp;Manel Njima ,&nbsp;Sarra Boukhris ,&nbsp;M.Adnene Laatiri","doi":"10.1016/j.lrr.2023.100404","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100404","url":null,"abstract":"<div><p>Noonan syndrome is a genetic disorder frequently caused by PTPN11 mutations. Patients with Noonan syndrome are characterized by facial dysmorphism, short stature and congenital heart defects and they have a reported predisposition to malignancies such as leukemia, and solid and central nervous system tumors. Here, we report a case of a 14-year-old boy with Noonan syndrome treated for T-cell acute lymphoblastic leukemia who presented with 2 concomitant abnormalities: cerebral abscess and high grade glioblastoma. This exceptional association exhibits to a poorer prognosis and may sometimes delay the diagnosis and therefore the therapeutic intervention.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000444/pdfft?md5=485634e1df05d16d4b5e9d39874e4c59&pid=1-s2.0-S2213048923000444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138558773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight","authors":"Claudia Ielo ,&nbsp;Francesca Fazio ,&nbsp;Serena Rocchi ,&nbsp;Ilaria Rizzello ,&nbsp;Katia Mancuso ,&nbsp;Elena Zamagni ,&nbsp;Michele Cavo ,&nbsp;Maria Teresa Petrucci","doi":"10.1016/j.lrr.2023.100399","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100399","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines. Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000390/pdfft?md5=4e2ddeb4f3340dbb5caa3b39552a8b51&pid=1-s2.0-S2213048923000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138467500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}